Curated News
By: NewsRamp Editorial Staff
September 08, 2026

Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial

Discuss on LinkedInDiscuss on X, formerly TwitterDiscuss on SubstackDiscuss on TelegramParticipate in discussion on BlueskyParticipate in discussion on MastodonView history of this news story on GitHub
Original Source

TLDR

  • Quantum BioPharma received FDA clearance for a phase 2 trial of Lucid-MS, gaining an edge in multiple sclerosis treatment with a novel PAD2 inhibitor.
  • Lucid-MS is a first-in-class drug that inhibits PAD2 to target demyelination, and it will be tested in a randomized, double-blind, placebo-controlled phase 2 trial.
  • Quantum BioPharma's Lucid-MS could improve multiple sclerosis care by addressing demyelination directly, potentially offering a new treatment option for patients.
  • Quantum BioPharma's Lucid-MS is a patented drug candidate that aims to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.

Impact - Why it Matters

This news matters because it marks a significant step forward in the treatment of multiple sclerosis, a chronic and often debilitating disease affecting millions worldwide. Unlike current therapies that broadly suppress the immune system, Lucid-MS targets the underlying mechanism of demyelination, potentially offering a more precise approach with fewer side effects. The FDA clearance for a phase 2 trial means the drug will soon be tested in people with MS, bringing it closer to potential approval. If successful, Lucid-MS could fill a critical gap in MS treatment, particularly for patients who do not respond adequately to existing therapies. Additionally, the collaboration with Massachusetts General Hospital and Harvard Medical School on a PET imaging tracer could enhance the ability to monitor demyelination and accelerate drug development. For investors, the analyst coverage and price target reflect confidence in Quantum BioPharma's pipeline, while the broader context of biopharma giants like Sanofi, Roche, and Biogen underscores the competitive landscape and the high unmet need in neurological diseases. This development not only impacts patients but also signals potential growth for the company and its shareholders.

Summary

Quantum BioPharma Ltd. (NASDAQ: QNTM) has received FDA clearance for its Investigational New Drug (IND) application to initiate a randomized, double-blind, placebo-controlled phase 2 trial of Lucid-MS in patients with multiple sclerosis (MS). According to a BioMedWire editorial, Lucid-MS (also known as Lucid-21-302) is a patented, first-in-class drug candidate that inhibits peptidyl arginine deiminase 2 (PAD2) to target demyelination rather than broadly suppressing the immune system. The editorial notes that Lucid-MS previously completed phase 1 testing in healthy volunteers, with favorable safety and tolerability reported. It also discusses Quantum BioPharma’s parallel research collaboration with scientists at Massachusetts General Hospital and Harvard Medical School involving a PET imaging tracer designed to quantify demyelination.

The coverage highlights recent analyst attention, including Rodman & Renshaw’s initiation of coverage with a Buy rating and $8 price target, as Quantum BioPharma prepares Lucid-MS for its first clinical testing in people with MS. The editorial places the company alongside broader biopharmaceutical developments involving Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN), spanning vaccines, ophthalmology and neurological diseases. To view the full press release, visit https://ibn.fm/cwPHa.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Quantum also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty rights. The company’s latest updates are available in its newsroom at https://ibn.fm/QNTM.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial

Blockchain registration record for this content